 |
Trials |
ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone reseptor positive breast cancerCancer type: Breast cancer Phase: II Principal Investigator: Kyte Jon Amund Country: NO Keywords: Norway, Oslo, luminal B breast cancer, nivolumab, ipilimumab, immunogenic chemotherapy Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03409198?term=ICON&cond=Breast+Cancer&cntry=NO&rank=1 |